<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477229</url>
  </required_header>
  <id_info>
    <org_study_id>QoLiRECT</org_study_id>
    <nct_id>NCT01477229</nct_id>
  </id_info>
  <brief_title>Quality of Life in RECTal Cancer - a Prospective Multicenter Cohort Study</brief_title>
  <acronym>QoLiRECT</acronym>
  <official_title>Quality of Life in RECTal Cancer - A Study Within the Scandinavian Surgical Outcomes Research Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Society of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assar Gabrielsson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Gothenburg Medical Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rectal cancer is a common type of cancer occuring more frequently in men but also common in
      women. Almost 60% of the patients survive 5-years and the treatment has been continuously
      developed in the last three decades. The aim of the QoLiRECT study is to increase the
      knowledge about symptoms, functional impairments, quality of life (QoL) and psychological and
      socioeconomic burden in an unselected population of rectal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rectal cancer is more frequent in men than in women and is relatively uncommon before the age
      of 50. The prognosis for rectal cancer has improved over the last decades2. Almost 60% of all
      patients survive more than five years, and because of advances in early detection and
      treatment, this number is expected to increase in the future1. Treatment of rectal cancer
      varies depending on the stage of the disease at diagnosis. For some patients, operation is
      the only treatment. For others, surgery is combined with radiotherapy, chemotherapy or both.
      The two most common operative procedures are the sphincter-preserving anterior resection (AR)
      and the abdominoperineal resection (APR) - the latter results in a permanent colostomy.
      Patients with generalised disease at diagnosis receive palliative treatment, which may
      include chemotherapy and radiotherapy as well as surgery.

      Rectal cancer comes with a high risk of local recurrence, i.e. return of the tumour within
      the pelvis after a presumed curative resection. Local recurrence is difficult to treat and
      often very painful and distressing for the patient. Some local recurrences will be candidates
      for second line surgery, as is also true for some distant metastases.

      The aim of the QoLiRECT study is to increase the knowledge about symptoms, functional
      impairments, quality of life (QoL) and psychological and socioeconomic burden in an
      unselected population of rectal cancer patients. Symptoms such as incontinence, pain, fatigue
      and impaired sexual function3 are common with this disease. Bodily changes, caused by the
      treatment or the disease itself, may lead to functional impairments and psychological,
      social, emotional and economical restraints. Conventional outcome measures such as morbidity
      and survival reveal little about these things.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients</measure>
    <time_frame>At diagnosis</time_frame>
    <description>It will be evaluated at diagnosis, , i.e. at presentation of a plan for the treatment, at 12 months after start of the treatment, regardless of which, at 24 months after start of the treatment and at 60 months after start of the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore potential differences in QoL, symptoms and functional impairments between subgroups of the population</measure>
    <time_frame>At diagnosis</time_frame>
    <description>and at 12 months, 36 months and 60 monts after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify symptoms and functional impairments and other risk factors that have great impact on QoL</measure>
    <time_frame>At diagnosis</time_frame>
    <description>will also be assessed at 12 months after start of the treatment, regardless of which, at 24 months after start of the treatment and at 60 months after start of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify patient and environmental factors with an impact on QoL</measure>
    <time_frame>At diagnosis</time_frame>
    <description>and at 12 months after start of the treatment, regardless of which, at 24 months after start of the treatment and at 60 months after start of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyse how clinical factors like oncologic result of operation, morbidity, recurrence and survival influence QoL</measure>
    <time_frame>At 12 months after start of the treatment</time_frame>
    <description>This will be analyzed regardless of which, at 24 months after start of the treatment and at 60 months after start of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To initiate interventional studies when appropriate</measure>
    <time_frame>12 months</time_frame>
    <description>May be another time frame than the one registered. Depends on results from the QoL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To generate basic descriptive data of the rectal cancer patient population: demography, socioeconomic data, disease stage at diagnosis, fashion of treatment, recurrence, survival</measure>
    <time_frame>At diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyse health economy aspects of QoL and morbidity in the patient population</measure>
    <time_frame>At diagnosis</time_frame>
    <description>and at 12 months after start of the treatment, regardless of which, at 24 months after start of the treatment and at 60 months after start of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the presence and impact of intrusive thoughts on QoL</measure>
    <time_frame>At 12 months</time_frame>
    <description>May be analyzed both at 24 and 60 months as well</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL in an unselected population of rectal cancer patients</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Quality of Life</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Abdominoperineal resection</arm_group_label>
    <description>Patients with low rectal cancers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anterior resection</arm_group_label>
    <description>Patients where it is possible to perform an anterior resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative chemo-radiation treatment</arm_group_label>
    <description>Patients with locally advanced rectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palliative treatment</arm_group_label>
    <description>Patients with systemic disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients presenting at the participating hospitals (both University Hospitals and
        Community Hospitals) with newly diagnosed rectal cancer, regardless of stage at diagnosis
        and plans for treatment, will be eligible for inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting at the participating hospitals with newly diagnosed rectal
             cancer, regardless of stage at diagnosis and plans for treatment, will be eligible for
             inclusion.

        Exclusion Criteria:

          -  Age below 18 years at diagnosis.

          -  No informed consent received or withdrawal of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Angenete, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SSORG - Scandinavian Surgical Outcomes Research Group and Sahlgrenska University Hospital in collaboration with Sahlgrenska Academy at University of Gothenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scandinavian Surgical Outcomes Research Group, SSORG, GÃ¶teborg</name>
      <address>
        <city>Gothenburg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.ssorg.net</url>
    <description>Study information</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Eva Angenete</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Abdominoperineal Resection</keyword>
  <keyword>Anterior Resection</keyword>
  <keyword>Palliative cancer treatment</keyword>
  <keyword>Radio chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

